Gilead Sciences Inc (NAS:GILD)
$ 64.6 -0.34 (-0.52%) Market Cap: 80.48 Bil Enterprise Value: 98.68 Bil PE Ratio: 179.39 PB Ratio: 4.61 GF Score: 74/100

Gilead Sciences Inc at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 05:40PM GMT
Release Date Price: $77.86 (-0.33%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Great. Good morning, everyone. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're really pleased to have Gilead with us. So we have Dan O'Day, Chairman and CEO; as well as Merdad Parsey, CMO.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

To start here, maybe we'll start with some big picture questions. Can you just give us a 30,000-foot view of where the company stands today and where the challenges have been, the accomplishments and then how you think of kind of the forward from here?

Daniel P. O;Day
Gilead Sciences, Inc. - Chairman & CEO

' -

Sure. So first of all, Salveen, great to be here with Merdad, and we're delighted to share some updates on Gilead. So at the 30,000-foot level, I think Merdad and I would say that we're really pleased with what's happened over the past 4 years. I mean just to remind you what our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot